Leap Therapeutics
47 Thorndike St, Suite B1-1
Cambridge
Massachusetts
02141
United States
Website: http://www.leaptx.com/
129 articles about Leap Therapeutics
-
In honor of World Cancer Research Day, BioSpace takes a deep dive into 10 therapeutic candidates with the potential to change the treatment landscape in lung, breast, colorectal cancer and more.
-
Leap Therapeutics to Participate at Upcoming September 2023 Investor Conferences
9/5/2023
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences.
-
Leap Therapeutics Reports Second Quarter 2023 Financial Results
8/14/2023
Leap Therapeutics, Inc. today reported financial results for second quarter ended June 30, 2023.
-
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
7/12/2023
Leap Therapeutics, Inc. today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (CRC) in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study.
-
Leap Therapeutics Announces Reverse Stock Split - June 20, 2023
6/20/2023
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced that it will effect a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023.
-
Leap Therapeutics Reports First Quarter 2023 Financial Results
5/15/2023
Leap Therapeutics, Inc. today reported financial results for first quarter ended March 31, 2023.
-
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
4/26/2023
Leap Therapeutics, Inc. today announced that the Company will be presenting new long-term follow-up data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from Part A of the DisTinGuish study, a Phase 2 clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01 at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
4/12/2023
Leap Therapeutics, Inc. today announced that enrollment has been completed in Part A of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody.
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
3/24/2023
Leap Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2022.
-
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
3/16/2023
Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced that BeiGene's option under the Exclusive Option and License Agreement between Leap and BeiGene granting rights in certain Asian territories to DKN-01, Leap's anti-DKK1 monoclonal antibody, has expired in accordance with the terms of the agreement.
-
Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc.
-
Leap Therapeutics Acquires Flame Biosciences
1/17/2023
Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022.
-
Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
1/11/2023
Leap Therapeutics, Inc. today announced that Douglas E. Onsi , President and Chief Executive Officer, Cynthia Sirard, MD, Chief Medical Officer, and Jason Baum, PhD., Vice President and Head of Translational Medicine will present a corporate overview at B. Riley Securities' 3rd Annual Oncology Conference.
-
Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference
11/21/2022
Leap Therapeutics, Inc. today announced that Douglas E. Onsi , President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held in New York.
-
Leap Therapeutics Reports Third Quarter 2022 Financial Results
11/14/2022
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2022.
-
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
10/17/2022
Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 antibody.
-
Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
10/12/2022
Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer (G/GEJ).
-
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
10/5/2022
Leap Therapeutics, Inc. today announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody.
-
Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference
9/7/2022
Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022.
-
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors
9/6/2022
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022.